Application of Immune Checkpoint Inhibitors in Common Gynecological Malignancies
DOI:
https://doi.org/10.53469/jcmp.2025.07(03).10Keywords:
Immunotherapy, Immune checkpoint inhibitors, Gynecological malignant tumors, Adverse eventsAbstract
Gynecological malignant tumors threaten women’s lives and property, among which cervical cancer, endometrial cancer, ovarian cancer and other malignancies have a high incidence rate and mortality trend with the change of women’s lifestyle and the aggravation of their psychological load in recent years. Therefore, standardized and efficient treatment of gynecological malignancies is crucial for maintaining long-term survival and a happy life for female patients. At present, immunotherapy has turn into the fourth cancer therapeutic tool after traditional operation, chemotherapy, and radiation therapy. In recent years, with the increasing attention to immunotherapy for gynecological tumors, immune checkpoint inhibitors is widely used in clinical practice of gynecological tumors in China, and their clinical efficacy is outstanding. This article summarizes clinical use and occurrence of adverse events of immune checkpoint inhibitors in gynecological tumors in recent years, and explores the therapeutic prospects of immune inhibitors in gynecological tumor diseases, in order to promote the development and innovation of tumor immunotherapy in the future.
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018), Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: A Cancer J for Clin, 68: 394-424.
Zhai Da, Wang Wenting, Gui Yuting, Zhang Lijun, Bai Chongyang, Ding Congcong & Zhai Hongye Retrospective analysis of allergen specific IgE test results of 12486 suspected allergic disease patients in Xi’an area from 2018 to 2023 [J]. Journal of Modern Laboratory Medicine (06), 167-173.
Terzic M, Aimagambetova G, Kunz J, Bapayeva G, Aitbayeva B, Terzic S, Laganà AS. Molecular Basis of Endometriosis and Endometrial Cancer: Current Knowledge and Future Perspectives [J]. Int J Mol Sci. 2021 Aug 27; 22(17):9274.
Gu Baoshuang, Zhao Caiqin, and Xu Fangfang (2025). The relationship between obesity, hyperglycemia, and hyperlipidemia and clinical characteristics of endometrial cancer patients [J]. Journal of Xinxiang Medical College (02), 133-137+142.
Huang Xianfeng, Zhou Xin & Zhou Feng Progress in histopathological diagnosis of endometrial precancerous lesions [J]. Journal of Diagnostic Pathology, 1-6.
Kong Beihua, Liu Jihong, Cui Heng, Wu Xiaohua, Huang He, Wang Xinyu &Martin (2025). Clinical Application Guidelines for PARP Inhibitors in Ovarian Cancer (2025 Edition) [J]. Progress in Modern Obstetrics and Gynecology (02), 81-94.
Mei Wentong, Wang Xueying, Xing Xiaofang & Ji Jiafu Progress and cutting-edge directions in tumor immunotherapy [J]. China Science Foundation 1-10.
Kong Beihua, Liu Jihong, Yin Aijun, Zhou Yun, Li Xiaoping, Gao Qinglei &Martin (2023). Clinical Application Guidelines for Immune [J]. Checkpoint Inhibitors in Gynecological Tumors (2023 Edition) Progress in Modern Obstetrics and Gynecology (05), 321-348.
Fu Qiang, Lu Zhongqi, Chang Ying, Jin Tiefeng&Zhang Meihua (2025). Research progress on immune checkpoint and anti-tumor effects of inhibitors [J]. Journal of Practical Medicine (02), 288-293.
Zhu Tong, Zeng Guanghong, and Zhou Jie (2024). The research progress of immune checkpoint inhibitors in the treatment of glioma [J]. Chinese Journal of Neurosurgery Disease Research (05), 87-91.
NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicity [E/OL]. Version 1.
Liu Y, Wu L, TongＲ, et al. PD-1 /PD-L1 inhibitors in cervical cancer[J]. Front Pharmacol, 2019, 10: 65.
Shao C, Li G, Huang L, et al． Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors[J]. JAMA Netw Open, 2020, 3(10): e2025109.
(2022). KEYNOTE-158 study shows that Pembrolizumab has significant efficacy in treating MSI-H/dMMR endometrial cancer patients who have been treated [J]. Journal of Practical Oncology (01), 19.
Wang M, Fan W, Ye M, et al． Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers[J]．Sci Rep, 2018, 8(1): 8990.
Chin CD, Fares CM, Campos M, et al. Association of PDL1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian [J]. Mod Pathol, 2020, 33(10): 2001-2010.
Qin Shukui, Guo Jun, Li Jin Chinese Society of Clinical Oncology (CSCO) Guidelines for Toxicity Management of Immune Checkpoint Inhibitors [M]. Beijing: People’s Health Press, 2019.
Sun Xiaoni & Cao Xiaohong (2025). Research progress on risk factors of immune checkpoint inhibitor related adverse events in lung cancer patients [J]. Journal of Clinical Pulmonary Medicine (03), 449-454.
Zhao Hong. Toxicity management of immune checkpoint inhibitors [J]. Journal of Yan’an University (Medical Science Edition), 2023, 21 (02): 1-7.
HELLMANNMD, PAZ-ARES L, CARORB, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. The New England Journal of Medicine, 2019, 381(21):2020-2031.
WANGDY, SALEMJE, COHENJV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis[J]. JAMA Oncoloy, 2018, 4(12):1721-1728.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Xiao Wang, Mei Chen
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
